Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company´s Microbiota-Derived Biotherapeutic Products
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.
Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is an unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding.
This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount.
“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life”, said Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable. “We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations”.
Inmunomet is a private medical group specialized in intolerances and gut dysbiosis related disorders with strong experience on the clinic. With this investment, Inmunomet is seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products. Inmunomet provides not only the funding but smart capital and synergies on the clinic, very well aligned with Microviable focus and providing access to the real-world clinical needs to address unmet challenges in human health.
About Microviable
Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focused on developing novel technologies and therapeutic products from the microbiota. Over the last years, Microviable lunched a disruptive product for microbiota sampling that has grown exponentially into an international market with clients across fifteen different countries. Moreover, it has developed a unique technology to store human microbiota for downstream therapeutic applications. Currently, Microviable’s platform together with its large and diverse proprietary bacterial culture collection, has enabled the development of two different products, a unique in its kind product of complete microbiota and rationally defined bacterial consortia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005270/en/
Contact information
Claudio Hidalgo Cantabrana, PhD
claudio.hidalgo@microviable.com
(+34)670034435
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare announces CE Mark for new digital 4D SPECT/CT system, StarGuide GX27.11.2025 13:06:00 EET | Press release
GE HealthCare today announced CE Mark for its new StarGuide™ GX system,i a new digital 4D SPECT/CT designed with excellent precision, clinical efficiency and impressive versatility. This milestone marks a significant moment in molecular imaging’s evolution, helping empower clinicians to expand research and help personalize care across a growing range of nuclear medicine applications and tracers – including the acquisition of alpha emitters. StarGuide GX comes at a pivotal time for the field of nuclear medicine. As complex diseases such as cancer, Alzheimer’s and cardiovascular disease become increasingly prevalent, the demand for precision diagnostics and targeted therapies is accelerating. StarGuide GX helps meet this need head-on, enabling clinicians to break free from energy-range limitations and image tracers with exceptional clarity. With growing demand for digital SPECT/CT – partially driven by the rise of theranostics – GE HealthCare’s innovation arrives as departments seek all-
Deetken Impact Expands Climate Finance Leadership as Canada Joins Inclusive Climate Action Fund27.11.2025 11:07:00 EET | Press release
Deetken Impact, a Canadian impact investment firm, is proud to partner with the Government of Canada and announce their CAD$106 million commitment in the new Inclusive Climate Action Fund (ICAF), a USD$300 million blended finance vehicle that will mobilize capital for climate finance initiatives across Latin America and the Caribbean (LAC). Announced at the 30th United Nations Climate Change Conference (COP30) in Belém, Brazil by the Honourable Julie Dabrusin, Canada’s Minister of Environment and Climate Change, ICAF will meaningfully contribute to sustainable and climate-resilient economies in LAC through the strategic provision of capital and technical assistance to companies and projects that drive climate mitigation and adaptation in key sectors such as clean energy, sustainable agriculture and agroforestry, and green finance. ICAF aims to achieve ambitious impacts including reducing, avoiding, or sequestering more than 5 million tCO2 and expanding access to climate solutions for 1
Infobip Unveils 2026 Trends Poised to Transform Customer Engagement and Digital Ecosystems27.11.2025 11:00:00 EET | Press release
Global cloud communications platform Infobip today announces its predictions for 2026, spotlighting transformative trends set to redefine how businesses engage customers and operate across sectors. Central to these shifts are the mainstream adoption of AI-powered agents, the expansion of super apps as integrated ecosystems, and the rise of privacy-first AI models enabling scalable, compliant automation. “2026 will be a breakthrough year as generative AI and omnichannel communication converge to redefine customer engagement and digital ecosystems,”said Silvio Kutić, CEO at Infobip. “Retail and eCommerce sectors are already leading the way with hyper-personalized experiences, while healthcare and finance are rapidly adopting AI-driven solutions to enhance patient care and security. Crucially, the future of customer service lies in a human-in-the-loop approach—where AI-powered automation works hand-in-hand with human expertise to deliver both efficiency and empathy. ” AI Agents will handl
Lenovo Leads the Circular IT Shift with a New Chapter to Extend Lifecycles for Aging Tech27.11.2025 10:27:00 EET | Press release
Lenovo today introduced Lenovo Certified Refurbishment Services, a new addition to its IT sustainability and lifecycle solutions portfolio, available in EMEA. The service gives organizations the ability to refurbish their existing Lenovo devices, restoring useful life and enabling redeployment to deliver cost savings, maximize IT budgets and reduce e-waste. Most businesses still follow a binary model for their device lifecycle and refresh strategies: extend the warranty or buy new. However, Lenovo’s Certified Refurbishment Services introduce a powerful third option, refurbishing existing Lenovo devices to be reused or repurposed internally, to avoid premature retirements, balance IT refresh programs and help maximize investment. With IT budgets under pressure and sustainability goals rising to the top of corporate agendas, businesses across Europe are seeking smarter ways to extend device value while reducing environmental impact. Lenovo’s new Certified Refurbishment Services fulfill t
Stefanini Group Announces Major 2026 Investment and Expansion in France During Brazil-France Forum27.11.2025 10:00:00 EET | Press release
Stefanini Group, a global tech consulting company with expertise in digital transformation and artificial intelligence solutions, today announces a significant, multi-faceted commitment to the French market. The company plans a major investment and strategic expansion throughout 2026. The announcement is timed to the participation of Marco Stefanini, Founder and Global CEO of Stefanini Group, in the technology panel at the LIDE Brazil–France Forum, scheduled in Paris for November 26–27, 2025. “France is a crucial hub for the next wave of global digital transformation. Our increased investment here reinforces our AI-First methodology for French enterprises, leveraging cutting-edge technology to accelerate their digital journey and drive a new era of efficiency and innovation,” said Marco Stefanini. The company is aiming to substantially strengthen its presence in France through a dual approach: AI-driven organic growth and targeted acquisition. The CEO's visit will culminate with a priv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom